Berger Montague PC is investigating the Board of Directors of ADMA Biologics, Inc. for potential breaches of fiduciary duty. This probe follows a series of legal challenges, including an existing securities fraud class action lawsuit.
On August 10, a separate law firm notified investors of a deadline for a class action alleging misrepresentations of the company's financial state. The allegations specifically involve revenue recognition and business practices. No market reaction followed this specific announcement.